search
EADV
Trends
- 1EADV Congress 2026 Opens With Six Key Takeaways▼EADV Congress 2026: Day 1 Recap — 6 Headlines to Know
The European Academy of Dermatology and Venereology has begun its 2026 Congress, with day one producing six headline developments in dermatology. Coverage highlights new research presentations, treatment updates and clinical findings announced at the meeting, which draws skin-health specialists from around the world each year.
- 2New Biomarker Data on Rezpegaldesleukin Presented at EADV Congress 2026●New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
New biomarker data on rezpegaldesleukin were presented in a late-breaking oral presentation at the EADV Congress 2026. The findings show early molecular responses to the drug across multiple immune pathways that are dysregulated in patients with atopic dermatitis. The data suggest the therapy, an immune-regulating treatment, is being positioned as a potential option for the inflammatory skin condition, and the presentation is drawing attention from the dermatology community.
- 3CytoAgents Unveils New Preclinical Data on CTO1681●CytoAgents Presents New Preclinical CTO1681 Data at the 2026 EADV Congress
CytoAgents presented new preclinical data on its investigational compound CTO1681 at the 2026 EADV Congress, the European Academy of Dermatology and Venereology's annual meeting. The company says the findings support the drug candidate's development potential in dermatology. Details of the data and the indication being targeted have not been broadly reported, and the announcement is drawing attention from investors and dermatology specialists following the congress presentation.